Taylor Jacob M, Oladitan Leah, Carlson Susan, Hamilton-Reeves Jill M
Department of Nutrition Services, Children's Mercy Hospital & Clinics, 2401 Gillham Road, Kansas City, MO, 64108, USA,
Pediatr Nephrol. 2015 Oct;30(10):1815-23. doi: 10.1007/s00467-015-3115-5. Epub 2015 May 1.
Pretreating renal formulas with medications to lower the potassium and phosphorus content is common in clinical practice; however, the effect of this treatment on other nutrients is relatively unstudied. We examine whether nutrient composition is affected by pretreating renal formulas with sodium polystyrene sulfonate (SPS) suspension and sevelamer carbonate.
Fixed medication doses and treatment times were utilized to determine changes in the nutrient composition of Suplena® and Similac® PM 60/40. The effect of simultaneously adding both medications (co-administration) to the formula on the nutrient composition of Suplena® was also evaluated.
Pretreatment of Suplena® with SPS reduced the concentrations of calcium (11-38 %), copper (3-11 %), manganese (3-16 %), phosphorus (0-7 %), potassium (6-34 %), and zinc (5-20 %) and increased those of iron (9-34 %), sodium (89-260 %), and sulfur (19-45 %) and the pH (0.20-0.50 units). Pretreatment of Similac® PM 60/40 with SPS reduced the concentrations of calcium (8-29 %), copper (5-19 %), magnesium (3-26 %), and potassium (33-63 %) and increased those of iron (13-87 %) and sodium (86-247 %) and the pH (0.40-0.81 units). Pretreatment of both formulas with the SPS suspension led to significant increases in the aluminum concentration in both formulas (507-3957 %). No differences in potassium concentration were observed between treatment times. Unexpectedly, the levels of neither phosphorus nor potassium were effectively reduced in Suplena® pretreated with sevelamer carbonate alone or when co-administered with SPS.
Pretreating formula with medications alters nutrients other than the intended target(s). Future studies should be aimed at predicting the loss of these nutrients or identifying alternative methods for managing serum potassium and phosphorus levels in formula-fed infants. The safety of pretreating formula with SPS suspension should also be examined.
在临床实践中,使用药物预处理肾用配方奶粉以降低钾和磷含量很常见;然而,这种处理对其他营养素的影响相对较少被研究。我们研究用聚苯乙烯磺酸钠(SPS)混悬液和碳酸司维拉姆预处理肾用配方奶粉是否会影响其营养成分。
采用固定的药物剂量和处理时间来确定苏普乐(Suplena®)和雅培亲护(Similac®)PM 60/40营养成分的变化。还评估了将两种药物同时添加到配方奶粉中(联合给药)对苏普乐营养成分的影响。
用SPS预处理苏普乐可降低钙(11% - 38%)、铜(3% - 11%)、锰(3% - 16%)、磷(0% - 7%)、钾(6% - 34%)和锌(5% - 20%)的浓度,并提高铁(9% - 34%)、钠(89% - 260%)和硫(19% - 45%)的浓度以及pH值(0.20 - 0.50个单位)。用SPS预处理雅培亲护PM 60/40可降低钙(8% - 29%)、铜(5% - 19%)、镁(3% - 26%)和钾(33% - 63%)的浓度,并提高铁(13% - 87%)和钠(86% - 247%)的浓度以及pH值(0.40 - 0.81个单位)。用SPS混悬液预处理这两种配方奶粉均导致两种配方奶粉中的铝浓度显著升高(507% -